Stock GRTX GALERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.196 USD +10.11% Intraday chart for Galera Therapeutics, Inc. 0.00% +34.80%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Mar. 28 Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
GL
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
AQ
Galera Adopts Limited Duration Stockholder Rights Agreement
GL
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
GL
Galera Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
GL
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
AQ
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
GL
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
AQ
Galera Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
GL
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GL
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
GL
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
AQ
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
GL
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
GL
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
AQ
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
GL
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
AQ
Galera Therapeutics : Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRTX Stock
  4. News Galera Therapeutics, Inc.
  5. Press Releases